The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis

Intensive Care Medicine

Volumn 29, Issue 9, 2003, Pages 1464-1471

  Brun Buisson, Christian ^a   Roudot Thoraval, Françoise ^a   Girou, Emmanuelle ^a   Grenier Sennelier, Catherine ^a   Durand Zaleski, Isabelle ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Cost; Economic evaluation; Length of stay; Nosocomial infection; Sepsis; Septic shock

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK;

COSTS AND COST ANALYSIS; CROSS INFECTION; FEMALE; FRANCE; HEALTH CARE SURVEYS; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; SEPSIS; SHOCK, SEPTIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0141566202     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-003-1877-x     Document Type: Article

References (26)

1. Bone RC, Balk RA, Cerra FB, Dellinger EP, Fein AM, Knaus WA, Schein RM, Sibbald WJ, the ACCP/SCCM Consensus Conference Committee (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1656-1662
2. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Régnier B (1995) Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. JAMA 274:968-974
3. Brun-Buisson C, Doyon F, Carlet J (1996) Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. Am J Respir Crit Care Med 154:617-624
4. Pittet D, Thiévent B, Wenzel RP, Li N, Auckenthaler R, Suter PM, Thievent B (1996) Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients. Am J Respir Crit Care Med 153:684-693
5. Rangel-Frausto MS, Pittet D, Costigan MD, Hwang T, Davis CS, Wenzel RP (1995) The natural history of the systemic inflammatory response syndrome. JAMA 273:117-123
6. Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Kahn KL, Parsonnet J, Panzer R, Orav EJ, Snydman DR, Black E, Schwartz JS, Moore R, Johnson BL, Platt R (1997) Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 277:234-240
7. Pittet D, Rangel-Frausto S, Li N, Tarara D, Costigan M, Rempe L, Jebson P, Wenzel RP (1995) Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med 21:302-309
8. Barriere SL (1992) The economic impact of HA-1A (Centoxin) against endotoxin. Pharmacoeconomics 2:408-413
9. Chalfin DB, Holbein MEB, Fein AM, Carlon GC (1993) Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. JAMA 269:249-254
10. Schulman KA, Glick HA, Rubin H, Eisenberg JM (1991) Cost-effectiveness of HA-1A monoclonal antibodies for gram-negative sepsis: economic assessment of a new therapeutic agent. JAMA 266:3466-3471
11. Hout BA van, Birnie E, Redekop WK, Lorijn RH, Bossuyt PM, Rutten FF (1994) Cost-effectiveness of HA-1A treatment for patients with sepsis. Prog Clin Biol Res 388:435-43
12. Teres D, Rapoport J, Lemeshow S, Kim S, Akhras K (2002) Effects of severity of illness on resource use by survivors and nonsurvivors of severe sepsis at intensive care unit admission. Crit Care Med 30:2413-2419
13. Bernard GR, Vincent JL, Laterre PF, LaRosa SR Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709
14. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulmé R, Lepage E, Le Gall JR, The European Sepsis Group (2002) Epidemiology of sepsis and infection in ICU patients from an international multicenter cohort study. Intensive Care Med 28:108-121 (erratum p 526)
15. Kreger BE, Craven DE, Carling P, McCabe WR (1980) Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 68:332-343
16. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C (1999) A model to compute the medical cost of intensive care patients. Pharmacoeconomics 15:573-582
17. Sznajder M, Leleu G, Buonamico G, Auvert B, Aegerter P, Merlière Y, Dutheil M, Guidet B, Le Gall JR (1998) Estimation of direct cost and resource allocation in intensive care: correlation with Omega system. Intensive Care Med 24:582-589
18. Tierney WM, Fitzgerald JF, Miller ME, James MK, McDonald CJ (1995) Predicting inpatient costs with admitting clinical data. Med Care 33:1-14
19. Barnett PG (1997) Research without billing data. Econometric estimation of patient-specific costs. Med Care 35:553-563
20. Slatyer MA, James OF, Moore PG, Leeder SR (1986) Costs, severity of illness and outcome in intensive care. Anaesth Intensive Care 14:381-389
21. Thompson SG, Barber JA (2002) How should cost data in pragmatic randomised trials be analysed? BMJ 320:1197-1200
22. Pittet D, Tarara D, Wenzel RP (1994) Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 271:1598-1601
23. Linden PK, Angus DC, Chelluri L, Branch RA (1995) The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody. J Crit Care 10:154-164
24. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310
25. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C (2002) An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 347:993-1000
26. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C (1999) Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 282:1745-1751